Flash FinanceUS
Market open S&P 5007,376.86+0.31% Nasdaq24,579.42+1.09% Dow 3051,285.73-0.46% Russell 20002,754.11+0.89% Nasdaq-10026,989.99+1.35% MidCap 4003,602.50+0.56% SmallCap 6001,673.98+0.05% VIX25.64-9.01% 10Y Yield4.86+0.45% Close of Nov 06, 2026
AI brief of an SEC Form 8-K · GERON CORP (GERN)

Geron Q3 2026 net income of $1.4 million as RYTELO sales rise to $60.1 million

Positive Impact 4 of 5 earnings Written later

Geron reported third quarter 2026 product revenue of $60.1 million, up from $47.2 million a year earlier, and net income of $1.4 million, compared with a net loss of $18.4 million in the same quarter of 2025. The company kept its 2026 RYTELO revenue expectation at the mid-to-high end of $220 million to $240 million but lowered its total operating expense range to $220 million to $230 million, which is below the prior $230 million to $240 million range.

Key points

  • Q3 2026 total product revenue, net was $60.1 million, versus $47.2 million in Q3 2025, and RYTELO demand grew 10% from Q2 2026.
  • Q3 2026 net income was $1.4 million, or $0.00 per share, compared with a net loss of $18.4 million, or $0.03 per share, in Q3 2025.
  • 2026 total operating expense guidance was lowered to $220 million to $230 million from $230 million to $240 million.
  • Cash, cash equivalents, restricted cash and marketable securities were $339.4 million as of September 30, 2026.

The filing

CompanyGERON CORP (GERN)
Form8-K, current report
Filed with the SECNov 4, 2026, 7:12 AM ET
Accession number0001193125-26-446203

Items reported: 2.02 Results of Operations

Read the filing on SEC.gov ↗

Written by AI on Nov 9, 2026, 8:28 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on November 04, 2026.

Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.